Search for a report

ASIA PACIFIC INFLUENZA VACCINE MARKET FORECAST 2020-2028

  • You are here:
  • Home
  • Downloads
  • ASIA PACIFIC INFLUENZA VACCINE MARKET FORECAST 2020-2028

ASIA PACIFIC INFLUENZA VACCINE MARKET FORECAST 2020-2028

The Asia Pacific influenza vaccine market is estimated to project growth a CAGR of 6.92% during the forecast period of 2020-2028. The high prevalence of influenza, the rising healthcare spending, and improvements in the healthcare sector across India and China are the driving factors responsible for market growth in the region. In order to analyze the high growth of the Asia Pacific influenza vaccine market, the region is segregated into India, Japan, Vietnam, Thailand, South Korea, Australia & New Zealand, Indonesia, China, and the rest of Asia Pacific.

ASIA PACIFIC INFLUENZA VACCINE MARKET FORECAST 2020-2028

Asia Pacific Influenza Vaccine Market by Type (Quadrivalent Vaccine, Trivalent Vaccine) by Technology (Egg-based Technology, Cell-based Technology) by Age Group (Pediatric Age Group, Adult Age Group)  by Delivery Mode (Injection, Asal Spray) and by Geography.

Request free sample

The Asia Pacific influenza vaccine market is estimated to project growth a CAGR of 6.92% during the forecast period of 2020-2028. The high prevalence of influenza, the rising healthcare spending, and improvements in the healthcare sector across India and China are the driving factors responsible for market growth in the region.

In order to analyze the high growth of the Asia Pacific influenza vaccine market, the region is segregated into India, Japan, Vietnam, Thailand, South Korea, Australia & New Zealand, Indonesia, China, and the rest of Asia Pacific. In China, the number of deaths caused by influenza in 2019 was about the same as the flu deaths in 2018, and more than the combined deaths for 2016 and 2017. Winter is the peak season for influenza outbreaks. Japan suffered from a serious influenza outbreak in 2019. From January 21 to 27, an average of 57.09 influenza patients was reported per facility among around 5000 medical facilities in the country.

The rising H1N1 and the new coronavirus cases across the globe, has led to multiple speculations in countries like India. According to the experts, the H1N1 virus is not as contagious as the new coronavirus. The WHO recommends vaccines to prevent acquiring the virus. India does not have a seasonal vaccination program apart from Mission Indradhanush, and the introduction of influenza vaccination is a necessity. In South Korea, the health authorities are advising people to get influenza vaccination immediately as the number of people suffering from influenza has doubled in the past month. All of these circumstances will cumulatively lead to the growth of the market.

BioDiem is a pharmaceutical company developing and marketing vaccines and therapies for infectious diseases. BioDiem has two licensed partners in India and China. The company has developed BDM-1, a unique synthetic compound that especially treats infections.

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.


    1. RESEARCH SCOPE & METHODOLOGY
      • STUDY OBJECTIVES
      • SCOPE OF STUDY
      • METHODOLOGY
      • ASSUMPTIONS & LIMITATIONS
    2. EXECUTIVE SUMMARY
      • MARKET SIZE & ESTIMATES `
      • MARKET OVERVIEW
    3. MARKET DYNAMICS
      • PARENT MARKET ANALYSIS: VACCINE MARKET
      • MARKET DEFINITION
      •    KEY DRIVERS
        • GOVERNMENT IMMUNIZATION PROGRAMS TO ERADICATE AILMENTS FROM THE SOCIETY
        • RISE IN THE CASES OF INFLUENZA
        • TECHNOLOGY ADVANCEMENT
      •    KEY RESTRAINTS
        • HIGH COST OF DEVELOPMENT
        • LENGTHY PROCESS OF DEVELOPMENT
    1. KEY ANALYTICS
      • KEY INVESTMENT INSIGHTS
      •    PORTER’S FIVE FORCE ANALYSIS
        • BUYER POWER
        • SUPPLIER POWER
        • SUBSTITUTION
        • NEW ENTRANTS
        • INDUSTRY RIVALRY
      • OPPORTUNITY MATRIX
      • VENDOR LANDSCAPE
    2. MARKET BY TYPE
      • QUADRIVALENT VACCINE
      • TRIVALENT VACCINE
    3. MARKET BY TECHNOLOGY
      • EGG-BASED TECHNOLOGY
      • CELL-BASED TECHNOLOGY
    4. MARKET BY AGE GROUP
      • PEDIATRIC AGE GROUP
      • ADULT AGE GROUP
    5. MARKET BY DELIVERY MODE
      • INJECTION
      • NASAL SPRAY
    6. GEOGRAPHICAL ANALYSIS
      •    ASIA PACIFIC
        • CHINA
        • JAPAN
        • INDIA
        • SOUTH KOREA
        • AUSTRALIA & NEW ZEALAND
        • THAILAND
        • INDONESIA
        • VIETNAM
        • REST OF ASIA PACIFIC
    1. COMPANY PROFILES
      • MERCK
      • NOVARTIS AG
      • PFIZER, INC
      • SANOFI
      • BIODIEM
      • EMERGENT BIOSOLUTIONS
      • HOFFMANN-LA ROCHE LTD
      • GLAXOSMITHKLINE
      • ABBOTT
      • CSL LTD

    TABLE LIST

    TABLE 1: MARKET SNAPSHOT – INFLUENZA VACCINE

    TABLE 2: ASIA PACIFIC INFLUENZA VACCINE MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 3: ASIA PACIFIC INFLUENZA VACCINE MARKET, BY TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    TABLE 4: ASIA PACIFIC INFLUENZA VACCINE MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 5: ASIA PACIFIC INFLUENZA VACCINE MARKET, BY TECHNOLOGY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    TABLE 6: ASIA PACIFIC INFLUENZA VACCINE MARKET, BY AGE GROUP, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 7: ASIA PACIFIC INFLUENZA VACCINE MARKET, BY AGE GROUP, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    TABLE 8: ASIA PACIFIC INFLUENZA VACCINE MARKET, BY DELIVERY MODE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 9: ASIA PACIFIC INFLUENZA VACCINE MARKET, BY DELIVERY MODE, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    TABLE 10: ASIA PACIFIC INFLUENZA VACCINE MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 11: ASIA PACIFIC INFLUENZA VACCINE MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    FIGURES LIST 

    FIGURE 1: KEY INVESTMENT INSIGHTS

    FIGURE 2: PORTER’S FIVE FORCE ANALYSIS

    FIGURE 3: OPPORTUNITY MATRIX

    FIGURE 4: VENDOR LANDSCAPE

    FIGURE 5: ASIA PACIFIC INFLUENZA VACCINE MARKET, GROWTH POTENTIAL, BY TYPE, IN 2019

    FIGURE 6: ASIA PACIFIC INFLUENZA VACCINE MARKET, BY QUADRIVALENT VACCINE, 2020-2028 (IN $ MILLION)

    FIGURE 7: ASIA PACIFIC INFLUENZA VACCINE MARKET, BY TRIVALENT VACCINE, 2020-2028 (IN $ MILLION)

    FIGURE 8: ASIA PACIFIC INFLUENZA VACCINE MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2019

    FIGURE 9: ASIA PACIFIC INFLUENZA VACCINE MARKET, BY EGG-BASED TECHNOLOGY, 2020-2028 (IN $ MILLION)

    FIGURE 10: ASIA PACIFIC INFLUENZA VACCINE MARKET, BY CELL-BASED TECHNOLOGY, 2020-2028 (IN $ MILLION)

    FIGURE 11: ASIA PACIFIC INFLUENZA VACCINE MARKET, GROWTH POTENTIAL, BY AGE GROUP, IN 2019

    FIGURE 12: ASIA PACIFIC INFLUENZA VACCINE MARKET, BY PEDIATRIC AGE GROUP, 2020-2028 (IN $ MILLION)

    FIGURE 13: ASIA PACIFIC INFLUENZA VACCINE MARKET, BY ADULT AGE GROUP, 2020-2028 (IN $ MILLION)

    FIGURE 14: ASIA PACIFIC INFLUENZA VACCINE MARKET, GROWTH POTENTIAL, BY DELIVERY MODE, IN 2019

    FIGURE 15: ASIA PACIFIC INFLUENZA VACCINE MARKET, BY INJECTION, 2020-2028 (IN $ MILLION)

    FIGURE 16: ASIA PACIFIC INFLUENZA VACCINE MARKET, BY NASAL SPRAY, 2020-2028 (IN $ MILLION)

    FIGURE 17: ASIA PACIFIC INFLUENZA VACCINE MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)

    FIGURE 18: CHINA INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)

    FIGURE 19: JAPAN INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)

    FIGURE 20: INDIA INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)

    FIGURE 21: SOUTH KOREA INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)

    FIGURE 22: AUSTRALIA & NEW ZEALAND INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)

    FIGURE 23: THAILAND INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)

    FIGURE 24: INDONESIA INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)

    FIGURE 25: VIETNAM INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)

    FIGURE 26: REST OF ASIA PACIFIC INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)

    1. GEOGRAPHICAL ANALYSIS
      •    ASIA PACIFIC
        • CHINA
        • JAPAN
        • INDIA
        • SOUTH KOREA
        • AUSTRALIA & NEW ZEALAND
        • THAILAND
        • INDONESIA
        • VIETNAM
        • REST OF ASIA PACIFIC
    1. MARKET BY TYPE
      • QUADRIVALENT VACCINE
      • TRIVALENT VACCINE
    2. MARKET BY TECHNOLOGY
      • EGG-BASED TECHNOLOGY
      • CELL-BASED TECHNOLOGY
    3. MARKET BY AGE GROUP
      • PEDIATRIC AGE GROUP
      • ADULT AGE GROUP
    4. MARKET BY DELIVERY MODE
      • INJECTION
      • NASAL SPRAY

    To request a free sample copy of this report, please complete the form below :

    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.


      Choose License Type

      Buy Now